ACADIA Pharmaceuticals Inc. Capex per Share

Capex per Share of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capex per Share growth rates and interactive chart. Capex per share refers to the total amount of capital expenditures paid in a period divided by the weighted average number of shares outstanding. If a company has capex of $100 million and 10 million shares outstanding, capex per share is $10.


Highlights and Quick Summary

  • Capex per Share for the quarter ending March 30, 2021 was -0.01 (a -46.83% decrease compared to previous quarter)
  • Year-over-year quarterly Capex per Share decreased by -64.17%
  • Annual Capex per Share for 2020 was -0.05 (a 525.97% increase from previous year)
  • Annual Capex per Share for 2019 was -0.01 (a -53.61% decrease from previous year)
  • Annual Capex per Share for 2018 was -0.02 (a 151.52% increase from previous year)
  • Twelve month Capex per Share ending March 30, 2021 was -0.05 (a 1.47% increase compared to previous quarter)
  • Twelve month trailing Capex per Share increased by 82.26% year-over-year
Trailing Capex per Share for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
-0.05 -0.05 -0.04 -0.03
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capex per Share of ACADIA Pharmaceuticals Inc.

Most recent Capex per Shareof ACAD including historical data for past 10 years.

Interactive Chart of Capex per Share of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Capex per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.01
2020 -0.01 -0.01 -0.02 -0.01 -0.05
2019 -0.0 -0.0 0.0 -0.01 -0.01
2018 -0.0 -0.01 -0.0 -0.0 -0.02
2017 0.0 -0.0 -0.0 -0.0 -0.01
2016 -0.0 -0.0 -0.08 -0.0 -0.08
2015 -0.0 -0.0 -0.01 -0.01 -0.02
2014 -0.0 -0.0 0.0 0.0 -0.0
2013 -0.0 -0.0 -0.0 0.0 -0.01
2012 0.0 0.0 0.0 0.0 0.0
2011 0.0 0.0 0.0 0.0 0.0
2010 0.0 0.0 0.0 0.0

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.